Short Interest in BiomX Inc. (NYSEAMERICAN:PHGE) Increases By 426.4%

BiomX Inc. (NYSEAMERICAN:PHGE) was the target of a significant increase in short interest during the month of January. As of January 30th, there was short interest totaling 270,744 shares, an increase of 426.4% from the January 15th total of 51,433 shares. Currently, 17.5% of the company’s stock are short sold. Based on an average daily trading volume, of 5,798,754 shares, the short-interest ratio is currently 0.0 days. Based on an average daily trading volume, of 5,798,754 shares, the short-interest ratio is currently 0.0 days. Currently, 17.5% of the company’s stock are short sold.

BiomX Price Performance

Shares of BiomX stock opened at $6.54 on Wednesday. The business has a fifty day simple moving average of $3.27 and a two-hundred day simple moving average of $7.07. BiomX has a 1 year low of $1.50 and a 1 year high of $22.06. The company has a market capitalization of $10.40 million, a price-to-earnings ratio of -0.26 and a beta of 1.66.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in BiomX stock. Citadel Advisors LLC purchased a new stake in BiomX Inc. (NYSEAMERICAN:PHGE) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 161,781 shares of the company’s stock, valued at approximately $85,000. Citadel Advisors LLC owned 0.61% of BiomX as of its most recent SEC filing. 40.57% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating on shares of BiomX in a research report on Tuesday, November 25th. One investment analyst has rated the stock with a Buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $26.00.

About BiomX

BiomX Inc is a clinical-stage biotechnology company that specializes in developing precision bacteriophage therapies to target pathogenic bacteria in the human microbiome. By harnessing the natural ability of bacteriophages to selectively infect and lyse harmful bacterial strains, BiomX aims to restore microbial balance without disrupting beneficial commensal organisms. The company’s platform integrates phage discovery, formulation and genetic engineering to create tailored phage cocktails for a range of microbiome-associated diseases.

The company’s pipeline includes lead clinical candidates for gastrointestinal disorders such as pouchitis and ulcerative colitis, as well as programs addressing dermatological indications including acne and atopic dermatitis.